Kiadis and Biofrontera Merge to Form New Company

An agreement to merge their two companies and form a new company has been announced by Kiadis (Leverkusen, Germany) and Biofrontera (Leiden, The Netherlands). The new company will be called Aliga Pharmaceuticals AG and its headquarters will be in Leverkusen.

Aliga Pharmaceuticals will serve as a holding company with wholly owned subsidiaries in Leverkusen and Leiden. The new company combines strong drug discovery and development programs focused on pain and central nervous system diseases with a proprietary technology basis, thereby providing innovative drug candidates and R&D solutions for the biotech and pharmaceutical industries.

"Because of an ongoing collaboration between Kiadis and Biofrontera on a joint neuropathic pain program, the enormous potential that a merged company could offer became apparent,” said Dr. Gerard Dijkstra, CEO of the new company. "This merger represents an outstanding opportunity to develop a substantial biopharmaceutical business, based upon Biofrontera's and Kiadis' innovative product portfolio and pioneering drug discovery capabilities.” The company notes that it is the first European private biopharmaceutical business resulting from a German/Dutch across-the-border merger.




Related Links:
Kiadis
Biofrontera